Cargando…

Rechallenge with gefitinib following severe drug-induced hepatotoxicity in a patient with advanced non-small cell lung cancer: A case report and literature review

Gefitinib has come to be the most widely used epidermal growth factor receptor-tyrosine kinase inhibitor in the treatment of advanced non-small cell lung cancer (NSCLC) in Asian patients. Common side effects include mild to moderate skin rash and diarrhea, however, drug-induced liver injury of varyi...

Descripción completa

Detalles Bibliográficos
Autores principales: CHEN, XUEQIN, PAN, YUELONG, ZHANG, SHIRONG, CHEN, DADONG, YANG, SHAOYU, LI, XIN, MA, SHENGLIN
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3919904/
https://www.ncbi.nlm.nih.gov/pubmed/24527096
http://dx.doi.org/10.3892/ol.2013.1756
_version_ 1782303106660302848
author CHEN, XUEQIN
PAN, YUELONG
ZHANG, SHIRONG
CHEN, DADONG
YANG, SHAOYU
LI, XIN
MA, SHENGLIN
author_facet CHEN, XUEQIN
PAN, YUELONG
ZHANG, SHIRONG
CHEN, DADONG
YANG, SHAOYU
LI, XIN
MA, SHENGLIN
author_sort CHEN, XUEQIN
collection PubMed
description Gefitinib has come to be the most widely used epidermal growth factor receptor-tyrosine kinase inhibitor in the treatment of advanced non-small cell lung cancer (NSCLC) in Asian patients. Common side effects include mild to moderate skin rash and diarrhea, however, drug-induced liver injury of varying severity is overlooked in long-term gefitinib administration and rarely reported. The current case report presents a female Chinese NSCLC patient who developed severe gefitinib-induced hepatotoxicity and was rechallenged with gefitinib following a 3-month break. The patient achieved partial clinical remission but developed drug-induced grade 4 hepatotoxicity following gefitinib administration for 14 months. As an alternative, 4 cycles of chemotherapy were administered to control tumor progression. Following restoration of the patient’s liver function, gefitinib was rechallenged together with active hepatoprotective therapy. The patient presented good disease control and maintained normal liver function for >6 months. Thus, sequential chemotherapy and gefitinib rechallenge with hepatoprotective therapy may be a potential new treatment strategy for gefitinib-induced hepatotoxicity.
format Online
Article
Text
id pubmed-3919904
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-39199042014-02-13 Rechallenge with gefitinib following severe drug-induced hepatotoxicity in a patient with advanced non-small cell lung cancer: A case report and literature review CHEN, XUEQIN PAN, YUELONG ZHANG, SHIRONG CHEN, DADONG YANG, SHAOYU LI, XIN MA, SHENGLIN Oncol Lett Articles Gefitinib has come to be the most widely used epidermal growth factor receptor-tyrosine kinase inhibitor in the treatment of advanced non-small cell lung cancer (NSCLC) in Asian patients. Common side effects include mild to moderate skin rash and diarrhea, however, drug-induced liver injury of varying severity is overlooked in long-term gefitinib administration and rarely reported. The current case report presents a female Chinese NSCLC patient who developed severe gefitinib-induced hepatotoxicity and was rechallenged with gefitinib following a 3-month break. The patient achieved partial clinical remission but developed drug-induced grade 4 hepatotoxicity following gefitinib administration for 14 months. As an alternative, 4 cycles of chemotherapy were administered to control tumor progression. Following restoration of the patient’s liver function, gefitinib was rechallenged together with active hepatoprotective therapy. The patient presented good disease control and maintained normal liver function for >6 months. Thus, sequential chemotherapy and gefitinib rechallenge with hepatoprotective therapy may be a potential new treatment strategy for gefitinib-induced hepatotoxicity. D.A. Spandidos 2014-03 2013-12-11 /pmc/articles/PMC3919904/ /pubmed/24527096 http://dx.doi.org/10.3892/ol.2013.1756 Text en Copyright © 2014, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Articles
CHEN, XUEQIN
PAN, YUELONG
ZHANG, SHIRONG
CHEN, DADONG
YANG, SHAOYU
LI, XIN
MA, SHENGLIN
Rechallenge with gefitinib following severe drug-induced hepatotoxicity in a patient with advanced non-small cell lung cancer: A case report and literature review
title Rechallenge with gefitinib following severe drug-induced hepatotoxicity in a patient with advanced non-small cell lung cancer: A case report and literature review
title_full Rechallenge with gefitinib following severe drug-induced hepatotoxicity in a patient with advanced non-small cell lung cancer: A case report and literature review
title_fullStr Rechallenge with gefitinib following severe drug-induced hepatotoxicity in a patient with advanced non-small cell lung cancer: A case report and literature review
title_full_unstemmed Rechallenge with gefitinib following severe drug-induced hepatotoxicity in a patient with advanced non-small cell lung cancer: A case report and literature review
title_short Rechallenge with gefitinib following severe drug-induced hepatotoxicity in a patient with advanced non-small cell lung cancer: A case report and literature review
title_sort rechallenge with gefitinib following severe drug-induced hepatotoxicity in a patient with advanced non-small cell lung cancer: a case report and literature review
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3919904/
https://www.ncbi.nlm.nih.gov/pubmed/24527096
http://dx.doi.org/10.3892/ol.2013.1756
work_keys_str_mv AT chenxueqin rechallengewithgefitinibfollowingseveredruginducedhepatotoxicityinapatientwithadvancednonsmallcelllungcanceracasereportandliteraturereview
AT panyuelong rechallengewithgefitinibfollowingseveredruginducedhepatotoxicityinapatientwithadvancednonsmallcelllungcanceracasereportandliteraturereview
AT zhangshirong rechallengewithgefitinibfollowingseveredruginducedhepatotoxicityinapatientwithadvancednonsmallcelllungcanceracasereportandliteraturereview
AT chendadong rechallengewithgefitinibfollowingseveredruginducedhepatotoxicityinapatientwithadvancednonsmallcelllungcanceracasereportandliteraturereview
AT yangshaoyu rechallengewithgefitinibfollowingseveredruginducedhepatotoxicityinapatientwithadvancednonsmallcelllungcanceracasereportandliteraturereview
AT lixin rechallengewithgefitinibfollowingseveredruginducedhepatotoxicityinapatientwithadvancednonsmallcelllungcanceracasereportandliteraturereview
AT mashenglin rechallengewithgefitinibfollowingseveredruginducedhepatotoxicityinapatientwithadvancednonsmallcelllungcanceracasereportandliteraturereview